Combining SERS analysis of serum with PSA levels for improving the detection of prostate cancer. (3rd October 2018)

• Record Type: Journal Article
• Authors: Stefancu, Andrei; Moisoiu, Vlad; Couti, Razvan; Andras, Iulia; Rahota, Razvan; Crisan, Dana; Pavel, Ioana E; Socaciu, Carmen; Leopold, Nicolae; Crisan, Nicolae
• Is Part Of: Nanomedicine. Volume 13:Number 19(2018)
• Page Start: 2455
• Page End: 2467
• Publication Date: 2018-10-03
• Subjects: drop coating deposition -- principal component analysis-linear discriminant analysis -- prostate cancer -- prostate-specific antigen -- serum -- screening -- surface-enhanced Raman scattering; Nanotechnology -- Periodicals; Medical technology -- Periodicals; Nanotechnology -- Therapeutic use -- Periodicals; 610.28
• DOI: 10.2217/nnm-2018-0127
• Languages: English
• ISSNs: 1743-5889

Abstract

Aim: Previous studies regarding surface-enhanced Raman scattering (SERS) of serum have shown promising initial results in discriminating prostate cancer, a strategy which could complement standard tests such as the prostate-specific antigen (PSA).Materials & methods: SERS spectra of serum samples were combined with serum PSA levels to improve the discrimination accuracy between prostate cancer and nonmalignant pathologies in a cohort of 54 patients using principal component analysis-linear discriminant analysis (PCA-LDA).Results & discussion: Combining SERS spectra with serum PSA levels in a single PCA-LDA model could discriminate between the two groups with an overall accuracy of 94%, yielding better results than either method alone.Conclusion: These results highlight that combining SERS-based cancer screening with serum PSA levels represents a promising strategy for improving the accuracy of prostate cancer diagnosis.